Martek announces new infant formula customer
Israeli Company Medici Medical Ltd. signs supply and license agreement for Martek's DHA and ARA.
16/01/06 Martek Biosciences Corporation has announced that infant formula company Medici Medical Ltd. has signed a license agreement for use of Martek's docosahexaenoic acid (DHA) and arachidonic acid (ARA) in infant formula sold in Israel.
The omega-3 fatty acid DHA and the omega-6 fatty acid ARA are naturally present in breast milk. Clinical studies have demonstrated cognitive and visual benefits for those infants receiving DHA and ARA supplemented formula.
Martek's proprietary blend of DHA and ARA is the only source of these nutrients that the FDA has cleared for use in U.S. infant formula, and is currently being sold by the Company's licensees in supplemented formulas in over 60 countries around the world.
Martek Biosciences Corporation develops, manufactures and sells naturally produced products from microalgae and fungi. The Company's products include: (1) specialty, nutritional oils for infant formula that aid in the development of the eyes and central nervous system in newborns; (2) nutritional supplements and food ingredients that may play a beneficial role in promoting mental and cardiovascular health throughout life; and (3) powerful fluorescent markers for diagnostics, rapid miniaturized screening, and gene and protein detection.
